GlassScriptPhysician profile
Alden Leifer
NPI 1093740375
$2,656.33
in general payments reported to CMS, 2019-2025
20 companies · $884 in 2025
The $884 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $154 · 2021: $330 · 2022: $308 · 2023: $403 · 2024: $380 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.81 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $341.17 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Vyzulta |
| New World Medical,INC. | $278.60 | 2021-2025 | Streamline, Via360, Ahmed Glaucoma Valve |
| Allergan, INC. | $185.81 | 2019-2021 | |
| Alcon Vision LLC | $178.29 | 2022-2025 | Tryptyr, Eysuvis, Clareon Panoptix Pro |
| Tarsus Pharmaceuticals, INC. | $167.88 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $152.63 | 2019-2022 | |
| Oyster Point Pharma, INC. | $123.68 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $68.82 | 2019-2021 | |
| Harrow Eye, LLC | $51.19 | 2025 | Vevye |
| Dompe US, INC. | $50.27 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.19 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $38.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.34 | 2019-2020 | |
| Sight Sciences, INC. | $31.75 | 2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $22.24 | 2024 | |
| Ocular Therapeutix, INC. | $15.74 | 2022 | |
| Horizon Therapeutics Plc | $12.98 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $12.89 | 2023 | Cequa |
| Shire North American Group INC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alden Leifer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.